Drug Discovery World

JULY 5, 2023

MG: I am responsible for Agilent’s cancer segment. A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

Research 98

Research Protein Scientist Immune Response 98

Drug Discovery World

JULY 22, 2022

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kathrin Herbst, PhD, Director of Science & Business Development, Lightcast, on: ‘A new era of single-cell functional profiling for drug discovery’.

Antibody 62

Antibody Engineer Protein Scientist 62

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 52

Research In-Vitro In-Vivo Development 52